Regulation of MAPK signaling and implications in chronic lymphocytic leukemia

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126:454–462.
   PubMed Web of Science ®Google Scholar
• Tam CS, Seymour JF. A new prognostic score for CLL. Blood. 2014;124:1–2.
   PubMed Web of Science ®Google Scholar
• Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999;59:24–27.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior 99 clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944–4951.
   PubMed Web of Science ®Google Scholar
• Kröber A, Seiler T, Benner A, et al. V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416.
   PubMed Web of Science ®Google Scholar
• Guièze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015;126:445–453.
   PubMed Web of Science ®Google Scholar
• Gardner JR, Nahas MK, He J, et al. Extensive high-depth sequencing of longitudinal CLL samples identifies frequent mutations in MAP kinase signaling and novel mutations activating notch and beta-catenin. Blood. 2013;122:2858.
   Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–530.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Miletic AV, Alt FW, et al. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med. 2003;198:1595–1608.
   PubMed Web of Science ®Google Scholar
• Coughlin JJ, Stang SL, Dower NA, et al. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol. 2005;175:7179–7184.
   PubMed Web of Science ®Google Scholar
• Iritani BM, Eisenman RN. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA. 1999;96:13180–13185.
   PubMed Web of Science ®Google Scholar
• Yankee TM, Keshvara LM, Sawasdikosol S, et al. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain. J Immunol. 1999;163:5827–5835.
   PubMed Web of Science ®Google Scholar
• Rowland SL, DePersis CL, Torres RM, et al. Ras activation of Erk restores impaired tonic BCR signaling and rescues immature B cell differentiation. J Exp Med. 2010;207:607–621.
   PubMed Web of Science ®Google Scholar
• Li YY, Baccam M, Waters SB, et al. CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. J Immunol. 1996;157:1440–1447.
   PubMed Web of Science ®Google Scholar
• Shukla A, Rai K, Shukla V, et al. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood. 2016;127:2310–2321.
   PubMed Web of Science ®Google Scholar
• Shukla A, Cutucache CE, Sutton GL, et al. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model. Exp Hematol. 2016;44:30–37.
   PubMed Web of Science ®Google Scholar
• Mittal AK, Chaturvedi NK, Rai KJ, et al. Chronic lymphocytic leukemia cells in lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med. 2014;20:290.
   PubMed Web of Science ®Google Scholar
• Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112:188–195.
   PubMed Web of Science ®Google Scholar
• Cambier JC, Gauld SB, Merrell KT, et al. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol. 2007;7:633–643.
   PubMed Web of Science ®Google Scholar
• Mockridge CI, Potter KN, Wheatley I, et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109:4424–4431.
   PubMed Web of Science ®Google Scholar
• Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4:1088–1101.
   PubMed Web of Science ®Google Scholar
• Yaktapour N, Meiss F, Mastroianni J, et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014;124:5074–5084.
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113:3050–3058.
   PubMed Web of Science ®Google Scholar
• Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782–792.
   PubMed Web of Science ®Google Scholar
• Dühren-von Minden M, Übelhart R, Schneider D, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309–312.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313–4320.
   PubMed Web of Science ®Google Scholar
• Darzentas N, Hadzidimitriou A, Murray F, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia. 2010;24:125–132.
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119:4467–4475.
   PubMed Web of Science ®Google Scholar
• Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519–525.
   PubMed Web of Science ®Google Scholar
• Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116:945–952.
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007;109:4944–4951.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ren Y, Moore L, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010;90:144–155.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122:1891–1899.
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Chaudhuri AA, Rao DS, et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 2009;106:7113–7118.
   PubMed Web of Science ®Google Scholar
• Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604–608.
   PubMed Web of Science ®Google Scholar
• Hernández JÁ, Rodríguez AE, González M, et al. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica. 2009;94:364–371.
   PubMed Web of Science ®Google Scholar
• Lake D, Corrêa SA, Müller J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci. 2016;73:4397–4413.
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Miyake S, Band V, et al. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem. 1996;271:14554–14559.
   PubMed Web of Science ®Google Scholar
• Frank MJ, Dawson DW, Bensinger SJ, et al. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood. 2009;113:2478–2487.
   PubMed Web of Science ®Google Scholar
• Chen SS, Raval A, Johnson AJ, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2009;106:13433–13438.
   PubMed Web of Science ®Google Scholar
• Goodnow CC, Sprent J, de St Groth BF, et al. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature. 2005;435:590–597.
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007;109:2032–2039.
   PubMed Web of Science ®Google Scholar
• Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008;111:2685–2692.
   PubMed Web of Science ®Google Scholar
• Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755–764.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–574.
   PubMed Web of Science ®Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–1767.
   PubMed Web of Science ®Google Scholar
• Kitabayashi A, Hirokawa M, Miura AB. The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Int J Hematol. 1995;62:99–106.
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118:3470–3478.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood. 2007;110:4012–4021.
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Delforge A, De Bruyn C, et al. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma. 1999;35:445–453.
   PubMed Web of Science ®Google Scholar
• Puig-Kröger A, Sanz-Rodríguez F, Longo N, et al. Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells. J Immunol. 2000;165:4338–4345.
   PubMed Web of Science ®Google Scholar
• Pittner BT, Shanafelt TD, Kay NE, et al. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia. 2005;19:2264.
   PubMed Web of Science ®Google Scholar
• Dürig J, Nückel H, Hüttmann A, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood. 2003;101:2748–2755.
   PubMed Web of Science ®Google Scholar
• Jain N, O’Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015;126:463–470.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015;126:471–477.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Orthod. 2012;30:2820–2822.
   Google Scholar
• Fruman DA, Cantley LC. Idelalisib-a PI3Kδ inhibitor for B-cell cancers. N Engl J Med. 2014;370:1061.
   PubMed Web of Science ®Google Scholar
• Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370:2352–2354.
   PubMed Web of Science ®Google Scholar
• Tomlinson MG, Woods DB, McMahon M, et al. A conditional form of Bruton’s tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC gamma 2 in B cells. BMC Immunol. 2001;2:4–12.
   PubMedGoogle Scholar
• Chen SS, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833–843.
   PubMed Web of Science ®Google Scholar
• Crassini K, Stevenson WS, Mulligan SP, et al. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leuk Lymphoma. 2015;56:3407–3417.
   PubMed Web of Science ®Google Scholar
• Crassini K, Stevenson WS, Mulligan SP. MAPK-Erk1/2 pathway activation and survival of chronic lymphocytic leukemia (CLL) cells is induced by in vitro modeling of the tumor microenvironment and can be effectively inhibited using the MEK1 inhibitor MEK162. Blood. 2013;122:4192.
   Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2011;30:488–496.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19:1225–1231.
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18:1386–1394.
   PubMed Web of Science ®Google Scholar
• Brauner E, Gunda V, Borre PV, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7:17194–17211.
   PubMed Web of Science ®Google Scholar
• Gorgun G, Ramsay AG, Holderried TA, et al. Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 2009;106:6250–6255.
   PubMed Web of Science ®Google Scholar
• Gilling CE, Mittal AK, Chaturvedi NK, et al. Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1 . Br J Haematol. 2012;158:216–231.
   PubMed Web of Science ®Google Scholar
• Compagno M, Wang Q, Pighi C, et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature. 2017;542:489–493.
   PubMed Web of Science ®Google Scholar
• Kotani A, Kakazu N, Tsuruyama T, et al. Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc Natl Acad Sci USA. 2007;104:1616–1620.
   PubMed Web of Science ®Google Scholar